CivilsWisdom.
Updated · Today
Science & Technology May 21, 2026 6 min read Daily brief · #13 of 31

Injectable cosmetic products not permitted under law, says drug regulator CDSCO

The Central Drugs Standard Control Organisation (CDSCO) published a public notice listing injectable cosmetic products — including hyaluronic acid fillers, b...

GS2 (Health Governance) GS3 (Science & Technology)

What Happened

  • The Central Drugs Standard Control Organisation (CDSCO) published a public notice listing injectable cosmetic products — including hyaluronic acid fillers, botulinum toxin, and collagen injections — as not permitted under law as cosmetics.
  • CDSCO stated that no cosmetic may legally be administered by injection, as the statutory definition of "cosmetic" under Indian law pertains exclusively to externally applied products.
  • The regulator warned that manufacturers, importers, and distributors marketing these substances as cosmetics would face legal action under the Drugs and Cosmetics Act, 1940.
  • The notice drew a clear regulatory boundary: if these products are to be used clinically, they must be approved and regulated as drugs — not cosmetics — and administered only by qualified medical professionals.
  • The action addresses a growing grey market of injectable aesthetic products marketed as cosmetics to bypass drug regulation requirements, putting patient safety at risk.

Static Topic Bridges

Drugs and Cosmetics Act, 1940 — The Cosmetic–Drug Boundary

The Drugs and Cosmetics Act, 1940 provides separate definitions and regulatory pathways for drugs and cosmetics. "Cosmetic" (Section 3(aaa)) means any article intended to be rubbed, poured, sprinkled, sprayed on, or otherwise applied to the human body — all methods implying external application. "Drug" (Section 3(b)) includes all medicines for internal or external use in the diagnosis, treatment, mitigation, or prevention of disease, and substances affecting the structure or function of the body. An injectable product intended to modify the appearance of the skin clearly affects body structure, placing it within the "drug" category regardless of its marketed purpose.

  • Drugs and Cosmetics Act, 1940: enacted to regulate import, manufacture, distribution, and sale of drugs and cosmetics.
  • Section 3(aaa): cosmetic — external application only (rubbed, poured, sprinkled, sprayed, or introduced into the body as defined in earlier sub-sections, but explicitly NOT by injection in the CDSCO interpretation).
  • Section 3(b): drug definition — broad enough to include substances affecting body structure/function.
  • Misbranding (Section 17A): marketing a drug as a cosmetic (or vice versa) to avoid regulatory requirements constitutes misbranding.
  • Penalty for misbranded/adulterated cosmetics: imprisonment up to 3 years and/or fine under Sections 27–28.
  • Manufacturing licence: cosmetics require state-level licence (Schedule M-II GMP); drugs require Schedule M compliance with CDSCO oversight.

Connection to this news: CDSCO's notice is a statutory enforcement position — injectable products cannot be classified as cosmetics under Section 3(aaa), and marketing them as such constitutes misbranding under the Act.

CDSCO Enforcement Powers and Recent Regulatory Tightening

CDSCO's enforcement powers under the Drugs and Cosmetics Act include issuing public notices, cancelling import registrations, directing prosecution, and coordinating with State Drug Controllers for raids and seizures. In recent years, CDSCO has issued alerts on spurious drugs (under the "Not of Standard Quality" and "Spurious Drug Alerts" published monthly), banned fixed-dose combinations (FDCs) under Section 26A, and introduced stricter requirements for new drug approvals under the New Drugs and Clinical Trials (NDCT) Rules, 2019.

  • Section 26A, Drugs and Cosmetics Act: empowers the central government to prohibit manufacture, sale, or distribution of any drug/cosmetic in public interest.
  • Fixed-Dose Combination (FDC) bans: over 344 FDCs banned by government order in 2016; upheld partially by Supreme Court in Pfizer Ltd. v. Union of India (2018).
  • NDCT Rules, 2019: streamlined clinical trial approval; introduced fast-track approvals for orphan drugs and priority review drugs.
  • Medical Devices Rules, 2017: separate framework for devices; many aesthetic tools (laser, needles) fall under this.
  • New Cosmetics Rules, 2020 (draft): proposed under the Drugs and Cosmetics Act to tighten cosmetic quality standards; include restriction on prohibited ingredients.

Connection to this news: CDSCO's injectable cosmetics notice is consistent with a broader pattern of regulatory tightening — closing loopholes that allow pharmacologically active substances to evade drug-level scrutiny by being marketed as cosmetics.

New Drugs and Clinical Trials Rules, 2019 — Pathway for Injectable Aesthetic Products

If manufacturers wish to legitimately sell injectable products (such as botulinum toxin or hyaluronic acid fillers) in India, they must follow the drug approval pathway under the NDCT Rules, 2019. This requires demonstrating safety and efficacy through clinical trials (or submitting data from overseas trials for waiver), obtaining CDSCO approval (Form CT-04 for new drugs, CT-06 for accelerated approval), and complying with Schedule M Good Manufacturing Practices. Botulinum toxin formulations are listed under Schedule H (prescription only) in India, requiring a registered medical practitioner's prescription.

  • NDCT Rules, 2019: replaced the older Schedule Y framework; brought India closer to ICH (International Council for Harmonisation) standards.
  • New Drug definition under NDCT Rules 2019: any drug not used in India to a significant extent, or approved for less than 4 years.
  • Schedule H drugs: require prescription; cannot be sold over the counter; must be recorded in purchase/sale registers by pharmacists.
  • Schedule H1 (2013 amendment to D&C Rules): adds additional safeguards for certain scheduled drugs; requires non-refillable prescriptions.
  • Import of drugs: requires CDSCO import registration certificate (IRC); unapproved imports constitute smuggling under Customs Act.

Connection to this news: The regulatory pathway for injectable cosmetic-aesthetic products is the drug approval route — CDSCO's notice effectively tells the industry to either get drug approval or stop selling these products in India.

Consumer Safety and Adverse Event Reporting

The Pharmacovigilance Programme of India (PvPI), launched in 2010 and run by the Indian Pharmacopoeia Commission (IPC) at Ghaziabad, is the national system for monitoring adverse drug reactions (ADRs). Adverse events from injectable cosmetic products — including vascular occlusion, tissue necrosis, infection, and systemic botulism — should be reported to PvPI. The programme is linked to WHO's global pharmacovigilance database (VigiBase) administered by the Uppsala Monitoring Centre (UMC) in Sweden.

  • PvPI launched: 2010; National Coordination Centre: Indian Pharmacopoeia Commission, Ghaziabad.
  • Adverse Drug Reaction (ADR) monitoring: doctors, pharmacists, and consumers can report at adrpvpi.icmr.org.in.
  • WHO VigiBase: global ADR database; India is one of the 150+ member countries in the WHO Programme for International Drug Monitoring.
  • Known adverse events from unqualified injectable cosmetics: arterial occlusion → blindness; tissue necrosis; anaphylaxis; systemic botulism (in cases of overdose/mislabelled concentration).
  • Consumer Protection Act, 2019: products causing harm may attract product liability claims under Chapter VI.

Connection to this news: CDSCO's notice is also a patient safety measure — adverse events from unregulated injectables applied in beauty parlours and unqualified clinics are a documented public health problem that PvPI's ADR data would capture.

Key Facts & Data

  • Legal basis: Section 3(aaa), Drugs and Cosmetics Act, 1940 — cosmetics are externally applied only
  • Products in CDSCO notice: hyaluronic acid fillers, botulinum toxin, collagen injections
  • Penalty for misbranded cosmetics/drugs: up to 3 years imprisonment and/or fine (Sections 27–28, D&C Act)
  • Botulinum toxin: listed as Schedule H prescription drug under Drugs and Cosmetics Rules
  • Section 26A, D&C Act: central government power to ban drugs/cosmetics in public interest
  • NDCT Rules, 2019: current framework for new drug approval in India
  • PvPI launched: 2010; coordinated by Indian Pharmacopoeia Commission, Ghaziabad
  • FDC bans under Section 26A: 344+ FDCs banned in 2016; upheld in Pfizer Ltd. v. Union of India (2018)
  • CDSCO's SUGAM portal: online registration system for drugs, cosmetics, and medical devices
On this page
  1. What Happened
  2. Static Topic Bridges
  3. Drugs and Cosmetics Act, 1940 — The Cosmetic–Drug Boundary
  4. CDSCO Enforcement Powers and Recent Regulatory Tightening
  5. New Drugs and Clinical Trials Rules, 2019 — Pathway for Injectable Aesthetic Products
  6. Consumer Safety and Adverse Event Reporting
  7. Key Facts & Data
Display